Stock Market

Torrent Pharmaceuticals’ journey, in numbers

It did not chase US generics pricing, it chased Indian and emerging-market brand value through serial bolt-ons. Torrent Pharmaceuticals’ journey in numbers.

By · Markets professional · · 1 min read · 105 words

Torrent Pharmaceuticals’ journey, a branded-generics franchise built by serial bolt-ons. Torrent Pharmaceuticals’ journey, a branded-generics franchise built by serial bolt-ons.
Torrent Pharmaceuticals’ journey, in numbers.
Listen to this article
0:00/--:--
Key takeaways
  • Founded in 1972 in Ahmedabad, focused on cardiac and CNS branded generics for India.
  • It built anchor strength in cardiology, gastrology and neurology and expanded into Brazil, Germany and the Philippines.
  • Serial acquisitions, Elder, Unichem, Curatio, each added a therapy category.
  • By FY25 revenue topped ₹11,000 crore with profit above ₹1,800 crore and margins above 30%.
  • 1972 Uchitkumar Mehta founds Torrent Pharma in Ahmedabad, focused on cardiac and CNS branded generics for the Indian market.
  • 1990 It builds one of India’s strongest domestic branded-generic portfolios, with cardiology, gastrology and neurology as anchors.
  • 2005 It expands internationally, making Brazil, Germany and the Philippines significant geographies.
  • 2014 It acquires Elder Pharmaceuticals’ women’s-healthcare portfolio.
  • 2017 It acquires Unichem’s branded business in India.
  • 2022 It acquires Curatio Healthcare for ₹2,000 crore, adding paediatric dermatology.
  • 2024 Domestic-formulations momentum stays strong, with Brazil and Germany contributing.
  • FY25 Revenue tops ₹11,000 crore with profit above ₹1,800 crore and an operating margin above 30%.
  • 2025 Capex on new Dahej and Indrad facilities supports international markets, with domestic branded growth flagged as the structural compounder.
  • 2026 Torrent stands as one of the strongest branded-generics franchises in India.

Torrent did not chase the commodity pricing of US generics. It chased Indian and emerging-market brand value through a long series of bolt-on acquisitions, each one adding a category, the whole portfolio compounding. The result is one of the strongest branded-generics franchises in India. Here is the journey, year by year.

The pattern is the point

Torrent did not chase US generics commodity pricing; it chased Indian and emerging-market brand value through serial bolt-on acquisitions, each adding a category while the whole portfolio compounds. The strongest branded-generics franchise in India is also one of the strongest defensives in a rate cycle, with margins to match.

Frequently asked questions

What does Torrent Pharmaceuticals do?

It makes branded generic medicines, anchored in cardiology, gastrology and neurology, for India and emerging markets like Brazil, plus Germany.

How has it grown?

Through strong domestic brands and a string of acquisitions, Elder, Unichem and Curatio, each adding a therapy category to the portfolio.

Why are its margins so high?

A branded, domestic-led mix carries higher and more stable margins than commodity US generics, supporting margins above 30%.

Is this article financial advice?

No. It is a company history for general interest, not investment advice or a recommendation about Torrent Pharmaceuticals or any security. This blog is for information and general interest only. It is not investment advice or a recommendation to buy or sell any company or security. Figures and dates are drawn from public sources. COVER, DARK MODE · use this version on the dark site theme

Related analysis

Stock MarketStrides Pharma Science’s journey, in numbersIt sold two of its best businesses, raised cash, and rebuilt around a focused platform, Strides Pharma Science’s journey in numbers. Stock MarketWelspun Corp’s journey, in numbersLong-cycle engineering pays out when three end markets order at once, Welspun Corp’s journey in numbers, from line pipes to infrastructure. Stock MarketCummins India’s journey, in numbersThe same engine, in a different cycle, gets a different multiple, Cummins India’s journey in numbers, as data centres turn gensets structural.
X / Twitter LinkedIn YouTube